BioNTech Results Presentation Deck

BNT311 Phase 1/2: First-in-Human Study of DuoBody-PD-L1x4-1BB, A Next-Generation Bispecific Antibody Next Generation Immunomodulator Bispecific antibody* designed to induce an antitumor immune response by simultaneous and complementary PD-L1 26 blockade and conditional 4-1BB stimulation Mechanism of action of FC-silenced DuoBody-PD-L1x4-1BB Patients with metastatic, unresectable solid tumors who are not candidates for SoC N~61 T Cell TCR MHC-I/II Open-label, dose-escalation trial with expansion cohorts to evaluate safety Part 1 BNT311 dose escalation 4-1BB PD-L1* (tumor cell/APC) Expansion dose 100 mg PD-1 DuoBody-PD-L1x4-1BB PD-L1 DuoBody-PD-L1x4-1BB Tumor Cell Antigen-presenting cell T cell Myeloid cell Natural Killer cell Macrophage Expansion Cohorts n = up to 40 per cohort SoC, Standard of Care; NSCLC, Non-small Cell Lung Cancer; TNBC, Triple-negative breast cancer; SCCHN, Squamous cell carcinoma of the head and neck; *BNT 311 (GEN 1046) is partnered with Genmab based on 50/50 sharing of costs and profits NSCLC, Urothelial cancer, Endometrial cancer, TNBC, SCCHN, Cervical cancer 9 expansion cohorts are ongoing LOCAL LYMPH NODES APC NK TUMOR BIONTECH

View entire presentation